Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
The EU recommendation for odronextamab comes after a US rejection in March.